Redefining Bacterial Mechanics

Driving Microorganism
Mechanical Adaptation

A discovery platform for characterizing and manipulating bacterial cell mechanics to solve complex challenges in human and animal health.

Mission

A Silent Crisis

Antibiotics often fail not because bacteria are genetically resistant, but because they tolerate stress. In chronic conditions like Cystic Fibrosis and COPD, pathogens like M. abscessus and P. aeruginosa change their physical properties to survive host immunity and conventional antibiotics.

Most new antibiotics target genes assumed to be essential, but evolution lets bacteria mutate around them. We target something they cannot evolve away from: the mechanical cell state that lets them survive in the first place.

  • Targeting global markets in health, nutrition, and industry
  • Discovery of compounds driving mechanical change
  • Harnessing mechanical change in evolutionarily disparate species
High-Resolution Microscopy of Bacterial Biofilm
Science

Mechanical Morphotype Switching

We have discovered that bacterial pathogens actively switch into differentiated mechanical morphotypes affecting survival during host cell infection. The trajectory of switching into discrete mechanical morphotypes dictates whether bacterial pathogens will exhibit enhanced tolerance to antibiotics and host innate immunity.

Expanding on research published in Science Advances (Eskandarian et al. 2024)

Human & Animal Health

Characterizing chemical compounds that drive mechanical change to treat infections and improve physiological outcomes in both human and animal health industries.

Genetic Control

Specific bacterial genes regulate the mechanical cell state. Identifying these genes has provided us the ability to uncover new therapeutic targets.

AI Discovery Engine for Bacterial Mechanics
Platform

AI Discovery Engine

We integrate high-throughput biophysical profiling with generative AI to identify compounds that modulate the mechanical states enabling bacterial tolerance.

Generative AI Models

Utilizing Chemical Transformers to predict small molecules that target the genes regulating mechanical morphotypes.

Biological Validation

Validating lead candidates in host-relevant infection models to confirm attenuation of persistence and tolerance.

High-Throughput Sorting

Rapidly characterizing changes in cell stiffness and density within large compound libraries to identify mechanical hits.

Approach

Defining a New Paradigm for Treating Bacterial Infection

Antibiotics are meant to kill bacteria outright, but the selective pressure they create lets resistant mutants emerge and replace the original population. Our approach is different: we modulate the mechanical cell state itself, a fundamental property that virulence depends on. Change it, and the bacterium becomes susceptible again.

Characterized
Compound Discovery
General
Mechanism of Action
Cross
Sector Applications
Partners

Backed By

Supporting the compute and infrastructure behind MorphoEngine.

NVIDIA Inception Program
Amazon Web Services

Morphogenesis Bio is a member of the NVIDIA Inception Program and is supported by AWS cloud credits.

News

Recognition

September 2026

AHNTI Innovation Showcase Finalist

Morphogenesis Bio was selected as a Biopharma finalist for the Animal Health, Nutrition & Technology Innovation (AHNTI) Innovation Showcase, presenting at The Westin Copley Place in Boston, Oct 26-28, 2026.

View on AHNTI US 2026

Leadership Team

Combining expertise in microbiology, computational neuroscience, and business operations.

Vahan Manukyan

Vahan Manukyan

President | CFA, MBA

Co-Founder of multiple tech startups. Extensive experience leading finance & operations for VC-backed companies.

Haig A. Eskandarian

Haig A. Eskandarian

Chief Scientific Officer | PhD

Microbiologist & Host-Pathogen specialist. Institut Pasteur, EPFL, UCSF, Harvard University.

Mehran Spitmann

Mehran Spitmann

Chief Technology Officer | PhD

Computational Neuroscientist. Expert in AI models for biomarker discovery and computational modeling